Juno Financial Group LLC Invests $2.23 Million in Danaher Corporation $DHR

Juno Financial Group LLC acquired a new position in Danaher Corporation (NYSE:DHR) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 9,727 shares of the conglomerate’s stock, valued at approximately $2,227,000.

Other institutional investors have also recently modified their holdings of the company. JPL Wealth Management LLC acquired a new stake in Danaher during the third quarter worth about $25,000. WFA of San Diego LLC acquired a new stake in Danaher during the second quarter worth about $26,000. Elevated Capital Advisors LLC acquired a new stake in Danaher during the fourth quarter worth about $26,000. ANTIPODES PARTNERS Ltd acquired a new stake in Danaher during the third quarter worth about $27,000. Finally, TruNorth Capital Management LLC acquired a new stake in Danaher during the third quarter worth about $28,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Danaher news, EVP Gregory M. Milosevich sold 1,320 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $208.01, for a total transaction of $274,573.20. Following the transaction, the executive vice president owned 5,099 shares of the company’s stock, valued at approximately $1,060,642.99. The trade was a 20.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 10.80% of the company’s stock.

Danaher Stock Performance

NYSE DHR opened at $184.11 on Thursday. The company has a market cap of $130.30 billion, a PE ratio of 35.61, a price-to-earnings-growth ratio of 2.64 and a beta of 0.95. The stock’s 50 day simple moving average is $197.17 and its 200-day simple moving average is $214.35. Danaher Corporation has a 1-year low of $180.03 and a 1-year high of $242.80. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.87 and a quick ratio of 1.51.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.12. The business had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $6 billion. Danaher had a return on equity of 10.96% and a net margin of 14.89%.The business’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.88 earnings per share. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. As a group, equities research analysts anticipate that Danaher Corporation will post 8.39 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Friday, March 27th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.9%. This is an increase from Danaher’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Friday, March 27th. Danaher’s dividend payout ratio is presently 30.95%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on DHR. Argus set a $265.00 target price on Danaher in a report on Wednesday, January 14th. Leerink Partners raised their target price on Danaher from $260.00 to $270.00 and gave the stock an “outperform” rating in a report on Friday, January 16th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Danaher in a report on Friday, March 27th. KeyCorp reissued an “overweight” rating on shares of Danaher in a report on Thursday, January 29th. Finally, Wolfe Research dropped their price objective on Danaher from $260.00 to $230.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $243.20.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: EPS beat and slight guidance lift — Danaher beat Q1 non?GAAP EPS estimates and raised the upper end of FY2026 EPS guidance, driven by Bioprocessing and Life Sciences strength. Read More.
• Positive Sentiment: Analyst upgrade/raise from Evercore — Evercore raised its DHR target (to $232) and kept an outperform view, signaling some buy?side conviction on longer?term momentum. Read More.
• Neutral Sentiment: € senior?notes offering — Danaher priced €3.0B (net) of euro?denominated senior notes across 2028–2038 maturities to raise ~€2.98B net proceeds; this funds corporate needs (and potentially M&A) but increases outstanding debt capacity. Read More.
• Neutral Sentiment: Mixed longer?term analyst view — while several firms still carry Buy/Outperform ratings and a median multi?quarter target above current levels, recent updates show varied target changes across shops. Read More.
• Negative Sentiment: Multiple price?target cuts — Several major houses trimmed targets (examples: JPMorgan to $245, Guggenheim to $235, TD Cowen/Wells Fargo adjustments), putting near?term pressure on the stock. Read More. Read More. Read More.
• Negative Sentiment: Revenue miss and Diagnostics softness — headline revenue lagged expectations and management flagged weaker Diagnostics (Cepheid/respiratory seasonality), leaving questions about near?term demand. Read More.
• Negative Sentiment: Insider selling and investor positioning — recent disclosures and institutional shifts (noted in market trackers) may amplify selling pressure while the market digests the cadence of core growth versus FX and M&A execution risks. Read More.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.